The Future of Antiviral Chemotherapy

Over the past two decades, alongside the production of vaccines against many viruses, effective drugs have been developed for many other common viral infections. Initially, many of these drugs were available only for topical application because of their toxicity. However, advances in our knowledge o...

Descripción completa

Detalles Bibliográficos
Autores principales: Crowe, Suzanne, Mills, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 1988
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7135513/
https://www.ncbi.nlm.nih.gov/pubmed/3067915
http://dx.doi.org/10.1016/S0733-8635(18)30631-4
_version_ 1783518072917721088
author Crowe, Suzanne
Mills, John
author_facet Crowe, Suzanne
Mills, John
author_sort Crowe, Suzanne
collection PubMed
description Over the past two decades, alongside the production of vaccines against many viruses, effective drugs have been developed for many other common viral infections. Initially, many of these drugs were available only for topical application because of their toxicity. However, advances in our knowledge of viral replication and of the molecular and cellular mechanisms of antiviral action have identified virus-specific targets for chemotherapeutic intervention with fewer side effects.
format Online
Article
Text
id pubmed-7135513
institution National Center for Biotechnology Information
language English
publishDate 1988
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-71355132020-04-08 The Future of Antiviral Chemotherapy Crowe, Suzanne Mills, John Dermatol Clin Article Over the past two decades, alongside the production of vaccines against many viruses, effective drugs have been developed for many other common viral infections. Initially, many of these drugs were available only for topical application because of their toxicity. However, advances in our knowledge of viral replication and of the molecular and cellular mechanisms of antiviral action have identified virus-specific targets for chemotherapeutic intervention with fewer side effects. Elsevier Inc. 1988-10 2018-06-26 /pmc/articles/PMC7135513/ /pubmed/3067915 http://dx.doi.org/10.1016/S0733-8635(18)30631-4 Text en Copyright © 1988 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Crowe, Suzanne
Mills, John
The Future of Antiviral Chemotherapy
title The Future of Antiviral Chemotherapy
title_full The Future of Antiviral Chemotherapy
title_fullStr The Future of Antiviral Chemotherapy
title_full_unstemmed The Future of Antiviral Chemotherapy
title_short The Future of Antiviral Chemotherapy
title_sort future of antiviral chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7135513/
https://www.ncbi.nlm.nih.gov/pubmed/3067915
http://dx.doi.org/10.1016/S0733-8635(18)30631-4
work_keys_str_mv AT crowesuzanne thefutureofantiviralchemotherapy
AT millsjohn thefutureofantiviralchemotherapy
AT crowesuzanne futureofantiviralchemotherapy
AT millsjohn futureofantiviralchemotherapy

Ejemplares similares